Clinical Trial Update: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Palazestrant (OP-1250) versus standard of care for ER-positive, HER2-negative advanced/metastatic breast cancer is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Palazestrant (palazestrant)

Snippet

Sponsor: Olema Pharmaceuticals, Inc. | Conditions: Breast Cancer, Advanced Breast Cancer | Phase 3 | Status: RECRUITING